Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2015

View Archived Issues

SSA-37A: a neuroprotective agent that could modulate AD progression

BLZ-100: a Tumor Paint candidate for imaging skin cancer

Pyrazolopiperidines from Janssen show activity as brain-penetrant P2X7 receptor antagonists

Basilea Pharmaceutica in-licenses pan-RAF kinase inhibitors

Pfizer presents novel irreversible EGFR T790M inhibitors

Research reveals new roles for known biomarkers

NCI and Intrexon to collaborate on T-cell therapies for cancer

VLP Therapeutics enters dengue vaccine collaboration with Nagasaki University

Roche describes new neurogenesis modulators

Aurigene discloses PD-1 signaling inhibitors

Identification of novel spiro-hydantoins as SARMs

Humira approved in Europe to treat children with severe plaque psoriasis

Bayer Schering Pharma patents CCR2 antagonists

Compugen discloses VSTM5 polypeptides

U.S. investigators develop modified L-asparaginases

Natpara now available in the U.S.

Lilly agrees to supply pemetrexed for phase II trial of demcizumab in NSCLC

Novel sensor shows potential for blood ammonia management

Enzalutamide extends survival compared with bicalutamide in castration-resistant prostate cancer

U.K. Medical Research Council and UCB partner to discover monoclonal antibodies

Curis' CUDC-907 receives FDA orphan drug designation for DLBCL

FDA grants fast track status to Perosphere's anticoagulant antidote PER-977

EMA approves Vectibix for metastatic colorectal cancer expressing wild-type RAS

Rucaparib given breakthrough therapy designation for BRCA-mutated ovarian cancer

Supplemental NDA filed for Pradaxa for the setting of hip replacement surgery

BMS and uniQure team up to develop gene therapies for cardiovascular disease

Alkermes reports on phase II trial of olanzapine/samidorphan combination in schizophrenia

Celldex Therapeutics starts phase I/II trial of varlilumab and ipilimumab in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...